News & Updates
Filter by Specialty:
Biomarker-driven therapies superior to standard care in breast cancer
Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.
Biomarker-driven therapies superior to standard care in breast cancer
02 Nov 2023
Histologic margin status predicts relapse in lentigo maligna melanoma
Histologic margin status shows a robust association with progression for lentigo maligna melanoma, suggest the results of a recent study.
Histologic margin status predicts relapse in lentigo maligna melanoma
26 Oct 2023
Niraparib tied to more toxicities than olaparib in ovarian cancer
Use of niraparib appears to contribute to a higher risk of haematological toxicities as compared with olaparib, suggests a study. The most common haematological adverse event is anaemia.
Niraparib tied to more toxicities than olaparib in ovarian cancer
25 Oct 2023
First-line therapies for advanced NSCLC improve survival, QoL
Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.
First-line therapies for advanced NSCLC improve survival, QoL
16 Oct 2023
Behavioural interventions improve screening colonoscopy uptake
Use of behavioural interventions, specifically multicomponent and patient navigation interventions, helps increase the uptake of colonoscopy for colorectal cancer (CRC) screening, reveals a study.
